Warfarin Patient Self-management Implementation in the US Healthcare System

Launched by UNIVERSITY OF UTAH · Feb 19, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on testing a new approach to managing warfarin therapy, which is a common medication used to prevent blood clots in conditions like atrial fibrillation, venous thromboembolism, and heart valve diseases. The researchers want to see if allowing patients to take charge of their own warfarin management—by monitoring their blood's clotting ability at home and making their own dosing decisions—can make the treatment safer, less burdensome, and more cost-effective than the usual method of having doctors manage it in a clinic.

To participate in this study, individuals must be at least 18 years old and have been on warfarin for at least nine months. They should be comfortable using a home device to test their blood levels or be able to quickly access their results from a clinic. Participants will need to test their blood every two weeks and have access to the internet for completing study forms. The study is currently recruiting participants, and those who join can expect to learn how to manage their medication more independently while being closely monitored throughout the process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years of age treated with warfarin for any indication for at least 9 months prior to enrollment
• • Demonstrate the willingness and ability to test their own INR using a home INR monitoring device or have same-day access to clinic-derived INR results (e.g., via electronic medical record secure messaging)
• • Willing to make independent decisions about warfarin dosing based on INR results
• • Able to perform INR tests at least every 2 weeks
• • Currently have and willing to maintain internet access for the duration of the study in order to complete online data collection forms
• • Have an anticipated duration of warfarin therapy of at least 6 months
• Exclusion Criteria:
• • Goal INR range other than 2.0-3.0 or 2.5-3.5
• • Known poor adherence to warfarin therapy
• • Non-English speaking
• • Inability or refusal to provide written informed consent